Antengene Corporation Limited provided consolidated earnings guidance for the six months ended June 30, 2022. Based on the preliminary unaudited consolidated management accounts of the Group for the six months ended June 30, 2022, the revenue of the Group for the six months ended June 30, 2022 is expected to be within the range of RMB 53.0 million to RMB 55.0 million, representing an increase from nil for the six months ended June 30, 2021. The increase in revenue was primarily attributable to the commercial launch of the first-in-class XPO1 inhibitor ® /XPOVIO® (Selinexor, ATG-010) in Mainland China on May 13, 2022.